(2R)-2-[3-[2-(2-methoxyethoxy)ethylamino]-3-oxopropyl]-4-oxohenicosanedioic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-2-[3-[2-(2-methoxyethoxy)ethylamino]-3-oxopropyl]-4-oxohenicosanedioic acid
• 化学式: C₂₉H₅₃NO₈
• 分子量: 543.7
• InChiKey: KAMVKEKUCSVZMF-RUZDIDTESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  38
• 可旋转键数：
  29
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Novel Glucagon Analogues
  申请人：NOVO NORDISK A/S

  公开号：US20160002311A1

  公开（公告）日：2016-01-07

  The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

  本发明涉及新型肽化合物，其具有持续的作用特性、改善的溶解度和稳定性，以及这些化合物在治疗中的应用，包括将这些化合物用于治疗需要的患者的治疗方法，以及将这些化合物用于制造药物的应用。本发明的化合物在治疗高血糖、糖尿病和肥胖症以及与高血糖、糖尿病和肥胖症相关的各种疾病或病况方面具有特别的意义。
• GLP-1 ANALOGUES AND DERIVATIVES
  申请人：Kalthoff Christoph

  公开号：US20130053311A1

  公开（公告）日：2013-02-28

  The invention relates to a GLP-1 analogue which comprises a histidine (H) residue at a position corresponding to position 31 of GLP-1 (7-37) (SEQ ID NO: 1), a glutamine (Q) residue at a position corresponding to position 34 of GLP-1 (7-37) (SEQ ID NO: 1), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37) (SEQ ID NO: 1); wherein the H residue is designated H 31 , and the Q residue is designated Q 34 ; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to derivatives thereof, as well as the pharmaceutical use of these analogues and derivatives, for example in the treatment and/or prevention of all forms of diabetes and related diseases. The invention furthermore relates to corresponding novel side chain intermediates. The derivatives are suitable for oral administration.

  本发明涉及一种GLP-1类似物，其包括一个组氨酸（H）残基，该残基位于对应于GLP-1（7-37）（SEQ ID NO：1）的31位位置，一个谷氨酰胺（Q）残基，该残基位于对应于GLP-1（7-37）（SEQ ID NO：1）的34位位置，并且与GLP-1（7-37）（SEQ ID NO：1）相比最多具有十个氨基酸修饰；其中，H残基被指定为H31，Q残基被指定为Q34；或其药学上可接受的盐、酰胺或酯。本发明还涉及其衍生物，以及这些类似物和衍生物的药用，例如用于治疗和/或预防所有形式的糖尿病和相关疾病。本发明还涉及相应的新型侧链中间体。这些衍生物适合口服给药。
• NOVEL GLUCAGON ANALOGUES
  申请人：Lau Jesper F.

  公开号：US20130035285A1

  公开（公告）日：2013-02-07

  The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
• LONG-ACTING Y2 RECEPTOR AGONISTS
  申请人：Kofoed Jacob

  公开号：US20130096055A1

  公开（公告）日：2013-04-18

  The present invention relates to PYY derivatives comprising a serum albumin binding side chain, wherein said derivative has a half-life of at least 7 hours as determined by Assay (IV) described herein as well as compositions comprising said derivative and its use in therapy.
• ANTAGONISTIC DR3 LIGANDS
  申请人：Novo Nordisk A/S

  公开号：US20140294853A1

  公开（公告）日：2014-10-02

  The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.